Total debt jumped from $1.3B to $4.2B within Q3 2026 and the debt-to-equity ratio rose from 0.19 to 0.61, while equity contracted from $11.9B in 2024Q3 to $6.8B, indicating a more leveraged and shrinking capital base.
Moderna, Inc. (MRNA) balance sheet — 10-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 |
|---|
| Total Current Assets | 7.34B | 6.54B | 8.1B | 10.32B | 13.43B | 16.07B | 6.3B | 1.13B | 1.56B | 783.22M | 1.09B |
| Cash & Short-Term Investments | 5.17B | 5.8B | 7.03B | 8.6B | 9.9B | 10.73B | 4.61B | 1.1B | 1.52B | 756.03M | 1.06B |
| Cash Only | 1.2B | 2.6B | 1.93B | 2.91B | 3.21B | 6.85B | 2.62B | 235.88M | 658.36M | 134.86M | 50.08M |
| Short-Term Investments | 3.98B | 3.2B | 5.1B | 5.7B | 6.7B | 3.88B | 1.98B | 867.12M | 863.06M | 621.17M | 1.01B |
| Accounts Receivable | 1.37B | 284M | 592M | 1.08B | 1.69B | 3.32B | 1.41B | 16.3M | 30.58M | 18.4M | 17.95M |
| Days Sales Outstanding | 68.7 | 53.32 | 67.55 | 57.62 | 32.58 | 68.39 | 639.69 | 98.8 | 82.65 | 32.64 | 60.45 |
| Inventory | 313M | 153M | 117M | 202M | 949M | 1.44B | 47M | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 44.77 | 64.34 | 29.17 | 15.71 | 63.96 | 200.98 | 437.81 | - | - | - | - |
| Other Current Assets | 493M | 45M | 58M | 88M | 44M | 26M | 11M | 1.03M | 595K | 951K | 0 |
| Total Non-Current Assets | 6.12B | 5.79B | 6.04B | 8.1B | 12.43B | 8.6B | 1.04B | 460.62M | 399.14M | 301.27M | 330.01M |
| Property, Plant & Equipment | 2.72B | 2.85B | 2.96B | 2.66B | 2.14B | 1.38B | 387M | 287.91M | 211.98M | 139.03M | 81.21M |
| Fixed Asset Turnover | 0.91x | 0.68x | 1.08x | 2.58x | 8.82x | 12.82x | 2.08x | 0.21x | 0.64x | 1.48x | 1.33x |
| Goodwill | 0 | 52M | 52M | 52M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 45M | 40M | 44M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 9.49B | 2.34B | 2.51B | 4.74B | 8.36B | 6.84B | 639M | 159.99M | 172.99M | 145.85M | 236.57M |
| Other Non-Current Assets | 596M | 421M | 407M | 523M | 946M | 46M | 13M | 12.72M | 14.18M | 16.38M | 12.23M |
| Total Assets | 13.47B | 12.34B | 14.14B | 18.43B | 25.86B | 24.67B | 7.34B | 1.59B | 1.96B | 1.08B | 1.42B |
| Asset Turnover | 0.21x | 0.16x | 0.23x | 0.37x | 0.73x | 0.72x | 0.11x | 0.04x | 0.07x | 0.19x | 0.08x |
| Asset Growth % | -20.08% | -12.76% | -23.25% | -28.74% | 4.82% | 236.23% | 361.61% | -19% | 80.93% | -23.47% | - |
| Total Current Liabilities | 2.03B | 1.99B | 2.21B | 3.02B | 4.92B | 9.13B | 4.39B | 143.12M | 222.8M | 191.46M | 162.8M |
| Accounts Payable | 259M | 317M | 405M | 520M | 487M | 302M | 18M | 7.09M | 31.21M | 20.73M | 28.16M |
| Days Payables Outstanding | 45.37 | 133.3 | 100.97 | 40.44 | 32.82 | 42.12 | 167.67 | 83.42 | 458.2 | 368.34 | 679.99 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 764M | 99M | 153M | 568M | 2.04B | 6.25B | 3.87B | 63.31M | 109.06M | 96.74M | 107.74M |
| Other Current Liabilities | 106M | 1.57B | 863M | 842M | 243M | 140M | 99M | 32.49M | 26.87M | 19.5M | 13.54M |
| Current Ratio | 3.62x | 3.29x | 3.67x | 3.42x | 2.73x | 1.76x | 1.43x | 7.89x | 7.02x | 4.09x | 6.68x |
| Quick Ratio | 3.47x | 3.22x | 3.62x | 3.36x | 2.54x | 1.60x | 1.42x | 7.89x | 7.02x | 4.09x | 6.68x |
| Cash Conversion Cycle | 68.1 | -15.64 | -4.26 | 32.88 | 63.72 | 227.25 | 909.82 | - | - | - | - |
| Total Non-Current Liabilities | 4.6B | 1.7B | 1.03B | 1.56B | 1.81B | 1.4B | 387M | 271.5M | 209.1M | 267.73M | 412.51M |
| Long-Term Debt | 3.55B | 1.24B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 2.6B | 673M | 710M | 1.22B | 1B | 705M | 207M | 132.36M | 33.49M | 15.69M | 12.5M |
| Deferred Tax Liabilities | 508M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 285M | -368M | 267M | 256M | 135M | 76M | 3M | 138K | 10.26M | 9.12M | 5.76M |
| Total Liabilities | 6.63B | 3.69B | 3.24B | 4.57B | 6.74B | 10.52B | 4.78B | 414.61M | 431.91M | 459.19M | 575.31M |
| Total Debt | 4.18B | 1.92B | 747M | 1.24B | 1.2B | 916M | 237M | 132.36M | 33.49M | 15.69M | 12.5M |
| Net Debt | 2.98B | -679M | -1.18B | -1.66B | -2B | -5.93B | -2.39B | -103.51M | -624.88M | -119.17M | -37.58M |
| Debt / Equity | 0.61x | 0.22x | 0.07x | 0.09x | 0.06x | 0.06x | 0.09x | 0.11x | 0.02x | 0.03x | 0.01x |
| Debt / EBITDA | -1.56x | - | - | - | 0.12x | 0.07x | - | - | - | - | - |
| Net Debt / EBITDA | -1.12x | - | - | - | -0.21x | -0.44x | - | - | - | - | - |
| Interest Coverage | -108.48x | -276.80x | -149.29x | -102.74x | 331.17x | 739.06x | -74.31x | -76.85x | -141.12x | -1938.36x | - |
| Total Equity | 6.84B | 8.65B | 10.9B | 13.85B | 19.12B | 14.14B | 2.56B | 1.17B | 1.53B | 625.3M | 841.85M |
| Equity Growth % | -101.84% | -20.65% | -21.32% | -27.55% | 35.19% | 452.32% | 117.99% | -23.23% | 144.72% | -25.72% | - |
| Book Value per Share | 15.90 | 22.24 | 28.39 | 36.27 | 45.97 | 32.82 | 6.72 | 3.55 | 4.65 | 1.66 | 13.13 |
| Total Shareholders' Equity | 6.84B | 8.65B | 10.9B | 13.85B | 19.12B | 14.14B | 2.56B | 1.17B | 1.53B | 625.3M | 841.85M |
| Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 34K | 33K | 6K | 6K |
| Retained Earnings | 5.26B | 7.22B | 10.04B | 13.61B | 18.32B | 9.96B | -2.24B | -1.5B | -1.01B | -621.89M | -365.72M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 8M | 45M | -10M | -123M | -370M | -24M | 3M | 1.8M | -1.32M | -1.16M | -403K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying MRNA stock.
As of 2025, Moderna, Inc. (MRNA) had total assets of $12.34B including $6.54B in current assets.
Moderna, Inc. (MRNA) carries total debt of $1.92B, offset by $5.80B in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Moderna, Inc. (MRNA) has total shareholders' equity (book value) of $8.65B ($22.24 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Moderna, Inc. (MRNA) reported a current ratio of 3.29x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Cash reserves declining against burn
Metrics are mathematically derived from official filings.
Balance Sheet Shrinking From Pandemic Peak
Based on reported figures, Moderna's total assets fell from $15.8B in 2024Q3 to $11.0B in 2026Q2 before recovering to $13.5B in 2026Q3, while equity contracted from $11.9B to $6.8B, indicating the balance sheet has been consumed by operating losses rather than rebuilt by earnings.
The decline in equity from roughly $11.9B to $6.8B is largely explained by accumulated losses reducing retained earnings from $11.2B to $5.3B over the period shown. The Q3 2026 rebound in total assets appears driven by a rise in liabilities and debt rather than retained profitability, which suggests the recovery should be read cautiously. Investors should monitor whether the asset base can be sustained without further dilution of the equity cushion.
Debt Rising Sharply Into Quarter-End
According to reported balance sheet data, total debt rose from $1.3B in 2026Q2 to $4.2B in 2026Q3, lifting the debt-to-equity ratio from 0.19 to 0.61 within a single quarter and marking the highest leverage in the ten-quarter window.
The jump in debt appears to be a deliberate financing decision rather than an operating necessity, given that cash was $1.2B at quarter end and had been higher previously. Leverage remains moderate in absolute terms but is rising against a shrinking equity base. The refinancing profile and maturity schedule are not disclosed in the supplied data, so the durability of this debt load warrants further investigation.
Cash Cushion Thinning Against Burn
As reported in financial statements, Moderna's cash position declined from $2.6B in 2025Q4 to $1.2B in 2026Q3, while the current ratio of 3.62 remains comfortable on paper, though the cash runway implied by the negative free cash flow margin of -122.3% appears limited.
A current ratio above 3 suggests short-term obligations are covered, yet this is largely a function of current assets that may include inventory and receivables rather than readily deployable cash. Cash has fallen by more than half over three quarters while the company continues to burn capital. This pattern suggests the buffer against commercial or regulatory shocks has narrowed materially.
Fixed Asset Base Stable, Goodwill Minimal
Based on Moderna's reported figures, net PP&E has held in a narrow band of roughly $2.7B to $3.2B across the period, while goodwill is only $52M, indicating impairment risk on the balance sheet is low even as the manufacturing footprint remains heavy.
The stable PP&E figure combined with the historically high fixed-cost manufacturing base suggests the asset-heavy model has not been scaled down in line with post-pandemic demand. Low goodwill means the balance sheet is not inflated by acquisition accounting, making tangible asset values a more direct read on capital employed. The risk here is less about write-offs of intangibles and more about whether the productive capacity can earn an adequate return.
Q3 Rebound Masks Structural Leverage Shift
Headline improvement in the Q3 2026 balance sheet may mislead, as total assets recovered to $13.5B while debt more than tripled from $1.3B and equity stayed near $6.8B, suggesting the apparent strength is financed rather than earned.
The most non-obvious distortion is that the asset recovery coincides with a sharp increase in debt and a falling retained earnings balance, so the headline asset figure does not reflect improved solvency. The deferred revenue swing from $442M to $407M and the current ratio fluctuations also show that working capital metrics are sensitive to timing of collections and milestone recognition. Based on reported figures, the quarter's positive earnings surprise has not yet translated into a stronger equity base, so this interpretation should be weighed against the sustained negative trailing margins.